Physician profile
Deborah Capshaw
NPI 1295186203
$3,746.18
in general payments reported to CMS, 2019-2025
22 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.11 · 2023: $380 · 2024: $2,837 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,599 · Travel and Lodging: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,598.73 |
| Travel and Lodging | $1,130.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,085.50 | 2024-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $344.52 | 2023-2025 | |
| Abbott Laboratories | $162.65 | 2024-2025 | Cardiomems, Jot Dx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.61 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $153.24 | 2021-2025 | Farxiga |
| Pfizer INC. | $137.34 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.42 | 2023-2025 | Eliquis, Camzyos |
| Amgen INC. | $94.20 | 2023-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $87.27 | 2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $58.89 | 2023 | Xarelto |
| Novo Nordisk INC | $48.15 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $35.86 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $34.47 | 2024-2025 | Uptravi, Opsynvi, Opsumit |
| Scpharmaceuticals INC. | $33.64 | 2024 | |
| Alnylam Pharmaceuticals INC. | $32.78 | 2025 | Amvuttra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.24 | 2023-2025 | |
| Edwards Lifesciences Corporation | $29.96 | 2024 | Sapien 3 Ultra Resilia |
| Organogenesis INC. | $23.31 | 2025 | Puraply Wound Matrix |
| Kiniksa Pharmaceuticals International, Plc | $22.51 | 2024 | Arcalyst |
| Atricure, INC. | $19.84 | 2024 | |
| Kestra Medical Technology Services, INC. | $19.03 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $16.75 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Capshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.